Cleveland Clinic continuous flow blood pump: progress in development

An anti-suction control for an intra-aorta pump using blood assistant index: a numerical simulation

With the extensive use of the left ventricular assist device (LVAD) as a treatment of heart failure, suction detection has become a key issue that directly affects the treatment. To detect the phenomenon of suction, a blood assistant index (BAI) is defined, which reflects the unloading level of the pump. The BAI is a ratio of the external work of LVAD and the input power of cardiovascular system. Using the theory of model-free adaptive control algorithm, an anti-suction controller, which chooses the heart rate and BAI as control variables, is designed. As a key feature, the proposed control algorithm adjusts the pump speed according to not only the blood demand of circulatory system but also the function of the native heart. Subsequently, the performance and robustness of the controller are evaluated using a numerical simulation of the assisted circulation and an in vitro experiment. The simulation and experimental results demonstrate that the BAI detects the suction occur accurately, and the controller can maintain the heart rate and BAI tracking the reference values with a response time of less than 6 s.

A control system for rotary blood pumps based on suction detection

A control system for rotary ventricular assist devices was developed to automatically regulate the pumping speed of the device to avoid ventricular suction. The control system comprises a suction detector and a fuzzy logic controller (FLC). The suction detector can correctly classify pump flow patterns, using a discriminant analysis (DA) model that combines several indices derived from the pump flow signal, to classify the pump status as one of the following: no suction (NS), moderate suction (MS), and severe suction (SS). The discriminant scores, which are the output of the suction detector, were used as inputs to the FLC. Based on this information, the controller updates pump speed, providing adequate flow and pressure perfusion to the patient. The performance of the control system was tested in simulations over a wide range of physiological conditions, including hypertension, exercise, and strenuous exercising for healthy, sick, and very sick hearts, using a lumped parameter model of the circulatory system coupled with a left ventricular assist device. The controller was able to maintain cardiac output and mean arterial pressure within acceptable physiologic ranges, while avoiding suction, demonstrating the feasibility of the proposed control system.

A rule-based controller based on suction detection for rotary blood pumps

A rule-based controller for rotary ventricular assist devices was developed to automatically regulate the pumping speed of the device without introducing suction in the ventricle. The control approach is based on a discriminant analysis function that detects the occurrence of suction, providing the input for the rule-based controller. This controller has been tested in simulations showing the ability to autonomously adjust pump flow according to the patient's level of activity, while sustaining adequate perfusion pressures. The performance of the system (suction detector and controller) was tested for several levels of activity and contractility state of the left ventricle, using a lumped parameter model of the circulatory system coupled with a left ventricular assist device. In all cases, the controller kept cardiac output and mean arterial pressure within acceptable physiologic ranges.

Development of the Baylor Gyro permanently implantable centrifugal blood pump as a biventricular assist device

The Baylor Gyro permanently implantable centrifugal blood pump (Gyro PI pump) has been under development since 1995 at Baylor College of Medicine. Excellent results were achieved as a left ventricular assist device (LVAD) with survival up to 284 days. Based on these results, we are now focusing on the development of a biventricular assist device (BVAD) system, which requires 2 pumps to be implanted simultaneously in the preperitoneal space. Our hypothesis was that the Gyro PI pump would be an appropriate device for an implantable BVAD system. The Gyro PI 700 pump is fabricated from titanium alloy and has a 25 ml priming volume, pump weight of 204 g, height of 45 mm, and pump diameter of 65 mm. This pump can provide 5 L/min against 100 mm Hg at 2,000 rpm. In this study, 6 half-Dexter healthy calves have been used as the experimental model. The right pump was applied between the infundibular of the right ventricle and the main pulmonary artery. The left pump was applied between the apex of the left ventricle and the thoracic descending aorta. As for anticoagulation, heparin was administered at the first postoperative week and then converted to warfarin sodium from the second week after surgery. Both pump flow rates were controlled maintaining a pulmonary arterial flow of less than 160 ml/kg/min for the sake of avoidance of pulmonary congestion. Blood sampling was done to assess visceral organ function, and the data regarding pump performance were collected. After encountering the endpoint, which the study could not keep for any reasons, necropsy and histopathological examinations were performed. The first 2 cases were terminated within 1 week. Deterioration of the pump flow due to suction phenomenon was recognized in both cases. To avoid the suction phenomenon, a flexible conduit attached on the inlet conduit was designed and implanted. After using the flexible inflow conduit, the required power and the rotational speed were reduced. Furthermore, the suction phenomenon was not observed except for 1 case. There was no deterioration regarding visceral organ function, and pulmonary function was maintained within normal range except for 1 case. Even though the experimental animal survived up to 45 days with the flexible inflow conduit, an increase in power consumption due to thrombus formation behind the impeller became a problem. Lower rotational speed, which was probably produced by the effectiveness of the flexible inflow conduit, was speculated to be one of the reasons. And the minimum range of rotational speed was 1,950 rpm in these 6 BVAD cases and the previous 3 cases of LVAD. In conclusion, 6 cases of BVAD implantation were performed as in vivo animal studies and were observed up to 45 days. The flexible inflow conduit was applied in 4 of 6 cases, and it was effective in avoiding a suction phenomenon. The proper rotational speed of the Gyro PI 700 pump was detected from the viewpoint of antithrombogenicity, which is more than 1,950 rpm.

In vivo hemodynamic performance of the Cleveland Clinic CorAide blood pump in calves

BACKGROUND

The Cleveland Clinic CorAide left ventricular assist system is based on a small implantable continuous-flow centrifugal blood pump with a completely suspended rotating assembly designed for long-term circulatory support (5 to 10 years).

METHODS

Between June 1999 and August 2000, the CorAide blood pump was implanted in 10 calves for 1 month and in 3 calves for 3 months.

RESULTS

The mean pump flow and arterial pressure were 6.1 +/- 1.1 L/min and 97 +/- 5 mm Hg, respectively. The mean plasma free-hemoglobin level after postoperative day 3 was 2.0 +/- 1.8 mg/dL. Renal and hepatic function remained normal in all cases. There was no incidence of mechanical failure, hemolysis, bleeding, or systemic organ dysfunction in any of the cases. Significant findings at autopsy were limited to two cases of renal infarction, one of which was associated with an outflow graft infection.

CONCLUSIONS

The CorAide blood pump is easily implanted, reliable, nonhemolytic, and nonthrombogenic, positioning it as a leading third-generation, continuous-flow left ventricular assist system with a completely suspended rotor.

Continuously maintaining positive flow avoids endocardial suction of a rotary blood pump with left ventricular bypass

This study showed the usefulness of maintaining positive pump flow to avoid endocardial suction and as an assist bypass. Three calves were implanted with centrifugal pumps. Hemodynamics and pump parameters were measured at varying pump speeds (from 1,100 to 2,300 rpm). In each test pump, speed was adjusted to create 3 hemodynamic states: both positive and negative flow (PNF), positive and zero flow (PZF), and continuously positive flow (CPF). The pump flow volume was determined during systole (Vs) and diastole (Vd). Vs in PNF was 29.6 ml and was not significantly different from Vs in PZF (p > 0.15). Vd in PNF was significantly different from Vd in PZF (p < 0.05). All bypass rates of PNF were over 30% of pulmonary flow. All PZF bypass rates were between the PNF rate and the CPF rate. These data showed that PZF satisfied the minimum requirement of assist flow and was under 100% bypass. Thus, PZF may avoid endocardial suction.

Sensorless controlling method for a continuous flow left ventricular assist device

We originated a novel control strategy for a continuous flow left ventricular assist device (LVAD). We examined our method by acute animal experiments to change the left ventricular (LV) contractility or LV end-diastolic pressure (LVEDP). To estimate the pump pulsatility without any specific sensor, we calculated the index of current amplitude (ICA) from motor current waveform. The ICA had a peak point (t-i point) that corresponded closely with the turning point from partial to total assistance, and a trough (s-i point) that corresponded with the beginning point of ventricular collapse. The pump flow at the t-i point (Qt-i) had no component of flow regurgitation. In the evaluation of the effects of preload LVEDP, afterload (mAoP), and contractility (max LV dp/dt), we found that preload was the only parameter that significantly influenced Qt-i. We concluded that our method could well control continuous flow LVAD by preventing reversed flow and ventricular collapse.

Future devices and directions

This article summarizes the status of left ventricular assist devices currently in the stages of bench testing, animal experiments, and pilot clinical trials. The major design features and estimate of costs for 17 devices are described under 3 major categories of indications for use: destination therapy, bridge to transplant, and bridge to recovery. A sleeved piston pump located in the aorta and a unique, magnetically suspended centrifugal pump are described in the destination therapy section. Eight centrifugal and 4 axial flow devices are listed in the bridge to transplant category, and an external cup and a very low-cost centrifugal pump with a left atrium-to-aorta circuit are described in the bridge to recovery section. The key design features of the future, which will be required for success in both the clinical and marketplace arenas, will be simplicity, safety, low-power requirements, and low cost.

Ultracompact, completely implantable permanent use electromechanical ventricular assist device and total artificial heart

An ultracompact, completely implantable permanent use electromechanical ventricular assist device (VAD) and total artificial heart (TAH) intended for 50-60 kg size patients have been developed. The TAH and VAD share a miniature electromechanical actuator that comprises a DC brushless motor and a planetary roller screw. The rotational force of the motor is converted into the rectilinear force of the roller screw to actuate the blood pump. The TAH is a one piece design with left and right pusher plate type blood pumps sandwiching an electromechanical actuator. The VAD is one half of the TAH with the same actuator but a different pump housing and a backplate. The blood contacting surfaces, including those of the flexing diaphragm and pump housing, of both the VAD and TAH were made of biocompatible polyurethane. The diameter, thickness, volume, and weight of the VAD are 90 mm, 56 mm, 285 cc, and 380 g, respectively, while those of the TAH are 90 mm, 73 mm, 400 cc, and 440 g, respectively. The design stroke volume of both the VAD and TAH is 60 cc with the stroke length being 12 mm. The stroke length and motor speed are controlled solely based on the commutation signals of the motor. An in vitro study revealed that a maximum pump flow of 7.5 L/min can be obtained with a pump rate of 140 bpm against a mean afterload of 100 mm Hg. The power requirement ranged from 4 to 6 W to deliver a 4-5 L/min flow against a 100 mm Hg afterload with the electrical-to-hydraulic efficiency being 19-20%. Our VAD and TAH are the smallest of the currently available devices and suitable for bridge to transplant application as well as for permanent circulatory support of 50-60 kg size patients.